文献速递消化道肿瘤与早癌消化内镜食管胃疾病与幽门螺杆菌

质子泵抑制剂使用与胃肿瘤内镜切除后幽门螺杆菌根除患者异时性胃癌风险:一项基于人群的队列研究

Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population-based cohort study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-08-17

该研究利用韩国国民健康保险数据库,纳入2009至2014年间因胃肿瘤接受内镜切除后行幽门螺杆菌根除治疗的患者,比较质子泵抑制剂(PPI)使用者(1836例)与非使用者(12218例)异时性胃癌的发生率。中位随访7.3年后,PPI使用与异时性胃癌风险升高相关,校正后风险比(HR)为5.51(95%CI 5.12-5.92),且不同累积剂量亚组及多种滞后分析和倾向性评分匹配后结果仍稳健。

要点

  • 长期使用PPI与内镜切除后幽门螺杆菌根除患者的异时性胃癌风险升高相关,校正后HR为5.51。
  • 无论累积PPI剂量高低,异时性胃癌风险升高均显著。
  • 多种时间滞后及倾向性评分匹配分析后,上述关联仍稳健。

核心结论

  • 长期使用PPI与胃肿瘤内镜切除后行幽门螺杆菌根除治疗的患者发生异时性胃癌的风险升高相关。

研究设计与样本

  • 基于韩国国民健康保险服务数据库的基于人群的队列研究。
  • 纳入2009至2014年间因胃肿瘤接受内镜切除后行幽门螺杆菌根除治疗的患者,其中PPI使用者1836例,非使用者12218例。
  • 比较PPI使用者与非使用者之间异时性胃癌的发生率,并进行多种时间滞后和倾向性评分匹配分析的敏感性分析。

主要发现

  • 中位随访7.3年,PPI使用者组异时性胃癌发生率显著高于非使用者组,粗风险比为6.20(95%CI 5.78-6.65)。
  • 校正后,PPI使用与异时性胃癌发生相关,校正风险比为5.51(95%CI 5.12-5.92)。
  • 按累积PPI剂量将PPI使用者分为三个亚组,无论PPI剂量高低,异时性胃癌风险升高均显著。
  • 应用多种时间滞后和倾向性评分匹配分析后,上述结果仍稳健。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between proton pump inhibitors (PPI) use and gastric cancer remains controversial. AIMS: To investigate the impact of long-term PPI use on metachronous gastric cancer after Helicobacter pylori eradication in high-risk patients who underwent endoscopic resection of gastric neoplasms. METHODS: Using the Korean National Health Insurance Services database, we identified 1836 PPI users and 12,218 non-users among patients who received H. pylori eradication therapy after endoscopic resection for gastric neoplasms between 2009 and 2014. We then compared the incidence of metachronous gastric cancer between the PPI user and non-user groups. We conducted sensitivity analysis using various time lags and propensity score-matched analysis to ensure the robustness of the results. RESULTS: After a median follow-up of 7.3 years, the incidence of metachronous gastric cancer was significantly higher in the PPI user group than in the non-user group, with a crude hazard ratio of 6.20 (95% confidence interval, 5.78-6.65). After adjustment, PPI use was associated with the development of metachronous gastric cancer, with an adjusted hazard ratio of 5.51 (95% confidence interval, 5.12-5.92). The PPI user group was categorised into three subgroups according to the cumulative PPI dose; the increased risk of metachronous gastric cancer remained significant regardless of the PPI dose. Moreover, these results remained robust after applying various time lags and propensity score-matched analyses. CONCLUSIONS: Long-term PPI use is associated with an increased risk of metachronous gastric cancer in patients who undergo H. pylori eradication therapy after endoscopic resection of gastric neoplasms.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Gong EJ, Jung HK, Lee B, et al. Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population-based cohort study. Aliment Pharmacol Ther. 2023. PMID: 37589510. doi:10.1111/apt.17676

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。